RollingStone Co

RollingStone Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of RollingStone Co (214610.KQ) as of Oct 21, 2026 is 77.48 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 39.03 % — a change of 98.50% (higher).

FCF Conversion

77.48 %

YoY

98.50%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of RollingStone Co is 2025 77.48 % . FCF Conversion Rate (FCF/EBITDA) of RollingStone Co was 2024 39.03 % . It decreases by 98.50% higher compared to the previous year.

The RollingStone Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
98.96 KRW
Jan 1, 2019
80.46 KRW
Jan 1, 2020
423.15 KRW
Jan 1, 2021
108.19 KRW
Jan 1, 2022
40.19 KRW
Jan 1, 2023
46.71 KRW
Jan 1, 2024
39.03 KRW
Jan 1, 2025
77.48 KRW
The RollingStone Co FCF Conversion history
YEARFCF ConversionYoY
77.48 %+98.50%
39.03 %-16.44%
46.71 %+16.23%
40.19 %-62.85%
108.19 %-74.43%
423.15 %+425.90%
80.46 %-18.69%
98.96 %+284.03%
25.77 %-70.54%
87.48 %+30.16%
67.21 %+12.14%
59.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RollingStone Co Stock analysis

What does RollingStone Co do? MiCo BioMed Co. Ltd. generates revenue through three business segments. The Molecular Diagnosis segment sells nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. The Biochemical Diagnosis segment supplies complex diagnostics, anemia meters, blood glucose meters, medical devices, and strips. The Immunodiagnostic Business segment produces and sells immunodiagnostic devices and immunodiagnostic kits. These products are sold to healthcare providers and medical facilities that require diagnostic tools for patient testing and analysis. The company's products target healthcare institutions including hospitals and clinics. Medical professionals use these devices for accurate diagnosis and treatment planning. The Biochemical Diagnosis segment's blood glucose meters and anemia meters are particularly used in point-of-care testing environments. The Molecular Diagnosis segment's gene amplification equipment supports laboratory-based genetic testing procedures. MiCo BioMed's business model focuses on direct sales to medical institutions and healthcare providers. The company does not mention any third-party distributors or online sales channels. Its product portfolio serves both hospital laboratories and outpatient diagnostic centers. The Immunodiagnostic Business segment's kits are designed for rapid testing applications in clinical settings. RollingStone Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RollingStone Co stock

FCF Conversion Rate (FCF/EBITDA) of RollingStone Co is 77.48 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of RollingStone Co changed from 39.03 % to 77.48 %, representing a 98.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) RollingStone Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s RollingStone Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RollingStone Co

All Key Metrics — RollingStone Co